EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer

Elias A Castro iD, Yash C Jani, Mehmet A Bilen

Journal of Immunotherapy and Precision Oncology · 12.05.2026 · 9 (2) · 62-78

DOI: 10.36401/jipo-25-22 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 12.05.2026. Verfasst von Elias A Castro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Die Arbeit nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is the most common non-cutaneous malignancy affecting men in the United States, with the incidence of metastatic disease rising. Despite modern androgen deprivation therapy (ADT), nearly all cases of metastatic prostate cancer develop castration resistance. Informed by successes in the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment modalities have emerged as part of the armamentarium for metastatic hormone-sensitive prostate cancer (mHSPC). In this review, we detail treatments such as cytotoxic chemotherapy, androgen receptor pathway inhibitors (ARPIs), radiotherapy, radiopharmaceutical therapy, immunotherapy, and poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of mHSPC, synthesizing current evidence and guiding clinical decision-making. With technological advances and insight from molecular studies, we discuss emerging biomarkers as indicators to guide prognostication and therapeutic decisions. As a result of these developments, the treatment landscape for mHSPC is evolving toward a precision oncology paradigm incorporating combined systemic therapies.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorsandrogen deprivation therapy (ADT)immunotherapymetastatic castration-resistant prostate cancer (mCRPC)metastatic hormone-sensitive prostate cancer (mHSPC)radioligand therapytumor biomarkers

Autor:innen und Institutionen

  • Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

ORCID-Profile: Elias A Castro

Zitieren

APA

Castro, E. A., Jani, Y. C., & Bilen, M. A. (2026). Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer. Journal of Immunotherapy and Precision Oncology, 9(2), 62-78. https://doi.org/10.36401/jipo-25-22

Vancouver

Castro EA, Jani YC, Bilen MA. Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer. Journal of Immunotherapy and Precision Oncology. 2026;9(2):62-78. doi:10.36401/jipo-25-22

BibTeX
@article{Castro2026,
  author = {Castro, Elias A and Jani, Yash C and Bilen, Mehmet A},
  title = {Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2026},
  volume = {9},
  number = {2},
  pages = {62--78},
  doi = {10.36401/jipo-25-22}
}
Kostenlos starten →